Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 12, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1

Prior Phase 1 Study Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause Current Phase 1/2 Study will Collect Symptom Relief and...
March 31, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update

Entered into an exclusive global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective U.S....
March 24, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast...
March 22, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will...
March 02, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in Upcoming Conferences

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that members of its management team will participate in the...
February 07, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in Upcoming Conferences

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
January 04, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in H.C. Wainwright BIOCONNECT 2022 Conference

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
December 07, 2021 16:15 ET | Source: Daré Bioscience, Inc.

Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis

Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosisThis marks the first FDA-approved product in Daré’s portfolio of potential first...
November 10, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update

Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3 ...
November 09, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...